匹多莫德对儿童哮喘合并反复呼吸道感染的疗效观察

目的 探讨哮喘合并反复呼吸道感染(RRI)经规律吸入糖皮质激素(ICS)症状控制不理想的儿童联用匹多莫德口服的临床疗效.方法 将2007年5月至2007年7月收治的哮喘合并RRI经系统ICS治疗控制不佳的患儿65例采用随机数字表分为两组,实验组(33例)在ICS的基础上加用匹多莫德颗粒口服2个月,对照组(32例)仅给予ICS吸入治疗.两组均随访12个月,记录RRI和哮喘发作情况、血液淋巴细胞亚群检测结果及不良反应.结果 与对照组比较,实验组的上呼吸道感染次数(t=5.205),下呼吸道感染次数(Z=2.056),哮喘发作次数(t=3.876),每次发作的发热天数(t=2.746)、咳嗽天数(Z=3.036)和抗生素使用天数(t=2.399)均少于对照组,差异有统计学意义(P均<0.05).与治疗前比较,实验组在治疗后2个月时CD3、CD4、CD8百分比和CD4/CD8比值均升高(t=3.783～13.490,P均<0.01);对照组治疗后CD3、CIM和CD4/CD8均低于实验组治疗后水平(f=4.107～7.209,P均<0.01).两组不良反应发生率差异无统计学意义(校正x2=0.378,P0.05).结论 哮喘合并RRI经ICS治疗控制不佳的儿童联用匹多莫德能有效预防RRI,减少哮喘的发作次数.匹多莫德颗粒疗效肯定,无明显不良反应,对RRI或哮喘合并RRI者可考虑使用.

Usefulness of pidotimod in asthmatic children combined with recurrent respiratory infection

Objective To investigate the therapeutic efficacy of pidotimod granules in bronchial asthmatic children combined with recurrent respiratory infection(RRI).Methods A randomized control trial was designed.Sixty-five children with ashtma combined with RRI,whose conditions were not being adequately controlled by inhaled corticosteroids(ICS),were randomly divided into two groups,the experimental group received ICS plus pidotimod granules and the control group received ICS only.The episodes of RRI and asthma,the ...